Recent advancements in lipid–mRNA nanoparticles as a treatment option for cancer immunotherapy

다국어 초록 (Multilingual Abstract)

Background Cancer remains a serious health concern worldwide, and different approaches are being developed for its treatment.
The strategy to use the immune system as an approach for treating cancer has recently gained momentum. Messenger RNA (mRNA) has been assessed as an up-and-coming resource for the evolution of advanced cancer immunotherapies over the past decades. However, degradation in extracellular compartments and during endosomal escape remain obstacles for efficient mRNA delivery and limit the therapeutic applications of this approach.
Area covered Lipid-based nanocarriers are gaining significant attention as non-viral mRNA vectors. Various lipid-based nanocarrier types have been developed to enhance the stability of mRNA molecules, facilitate their transfection, and ensure delivery to an intracellular compartment suitable for further processing. This review discusses the development of novel mRNA delivery systems using lipids for effective cancer immunotherapy.
Expert opinion mRNAs are superior to other biomolecules for developing therapeutic drugs and vaccines with multiple medical applications that are currently being explored by researchers in various biomedical fields. Lipid-based mRNA nanoparticles can improve the potency of the mRNA by enhancing its stability, enabling its cellular uptake, and facilitating its endosomal escape. Targetability of these therapeutics can be increased by conjugating their surface with the desired ligands or targeting agents. Lipid–mRNA nanoparticles are increasingly being incorporated in cancer immunotherapy applications, including vaccines, monoclonal antibodies, and chimeric antigen receptor T-cell treatment, and several such nanoparticles are being assessed in clinical trials. Further research that assesses key variables for transfection efficiency of lipid–mRNA nanoparticles will expedite the development of improved therapeutics.

참고문헌 (Reference)

1 Sahin U, "mRNA-based therapeutics—developing a new class of drugs" 13 : 759-780, 2014

2 Benteyn D, "mRNA-based dendritic cell vaccines" 14 : 161-176, 2015

3 Pardi N, "mRNA vaccines—a new era in vaccinology" 17 : 261-279, 2018

4 Namit Chaudhary, "mRNA vaccines for infectious diseases: principles, delivery and clinical translation" Springer Science and Business Media LLC 20 (20): 817-838, 2021

5 Wang Y, "mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma" 26 : 420-434, 2018

6 Reichmuth AM, "mRNA vaccine delivery using lipid nanoparticles" 7 : 319-334, 2016

7 Pantin J, "Upsetting the apple CAR-T(chimeric antigen receptor T-cell therapy)—sustainability mandates USA innovation" 190 : 851-853, 2020

8 Hajj KA, "Tools for translation : non-viral materials for therapeutic mRNA delivery" 2 : 17056-, 2017

9 Bus T, "The great escape : how cationic polyplexes overcome the endosomal barrier" 6 : 6904-6918, 2018

10 Akinc A, "The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs" 14 : 1084-1087, 2019

11 Hiam-Galvez KJ, "Systemic immunity in cancer" 21 : 345-359, 2021

12 Kranz L, "Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy" 534 : 396-401, 2016

13 Pichon C, "Synthetic messenger RNA and cell metabolism modulation (methods and protocols)" Humana Press 247-274, 2013

14 Miao L, "Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver" 11 : 2424-, 2020

15 Diken M, "Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation" 18 : 702-708, 2011

16 Cheng Q, "Selective organ targeting(SORT)nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing" 15 : 313-320, 2020

17 Ulkoski D, "Recent advances in polymeric materials for the delivery of RNA therapeutics" 16 : 1149-1167, 2019

18 Morille M, "Progress in developing cationic vectors for non-viral systemic gene therapy against cancer" 29 : 3477-3496, 2008

19 Tang J, "Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells" 3 : 6805-6812, 2015

20 Poudel K, "Photothermally modulatable and structurally disintegratable sub-8-nm Au1Ag9embedded nanoblocks for combination cancer therapy produced by plug-in assembly" 14 : 11040-11054, 2020

21 Wadhwa A, "Opportunities and challenges in the delivery of mRNA-based vaccines" 12 : 102-, 2020

22 Laura I. Selby, "Nanoescapology: progress toward understanding the endosomal escape of polymeric nanoparticles" Wiley 9 (9): 2017

23 Simões S, "Mechanisms of gene transfer mediated by lipoplexes associated with targeting ligands or pH-sensitive peptides" 6 : 1798-1807, 1999

24 Jayaraman M, "Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo" 51 : 8529-8533, 2012

25 Persano S, "Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination" 125 : 81-89, 2017

26 Chen W, "Lipopolyplex for therapeutic gene delivery and its application for the treatment of Parkinson’s disease" 8 : 68-, 2016

27 Zhang J, "Lipid–mRNA nanoparticle designed to enhance intracellular delivery mediated by shock waves" 11 : 10481-10491, 2019

28 Yuebao Zhang, "Lipids and Lipid Derivatives for RNA Delivery" American Chemical Society (ACS) 121 (121): 12181-12277, 2021

29 Love KT, "Lipid-like materials for low-dose, in vivo gene silencing" 107 : 1864-1869, 2010

30 Samaridou E, "Lipid nanoparticles for nucleic acid delivery: current perspectives" 154–155 : 37-63, 2020

31 Xucheng Hou, "Lipid nanoparticles for mRNA delivery" Springer Science and Business Media LLC 6 (6): 1078-1094, 2021

32 Aldosari BN, "Lipid nanoparticles as delivery systems for RNA-based vaccines" 13 : 206-, 2021

33 Cullis PR, "Lipid nanoparticle systems for enabling gene therapies" 25 : 1467-1475, 2017

34 Oberli MA, "Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy" 17 : 1326-1335, 2017

35 Maugeri M, "Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells" 10 : 4333-, 2019

36 Yasar H, "Kinetics of mRNA delivery and protein translation in dendritic cells using lipid-coated PLGA nanoparticles" 16 : 72-, 2018

37 Billingsley MM, "Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering" 20 : 1578-1589, 2020

38 Rush AM, "Intracellular mRNA regulation with self-assembled locked nucleic acid polymer nanoparticles" 136 : 7615-7618, 2014

39 De Haes W, "Internalization of mRNA lipoplexes by dendritic cells" 9 : 2942-2949, 2012

40 Karikó K, "In vitro transcribed mRNA therapeutics : out of the shadows and into the spotlight" 27 : 691-692, 2019

41 Hobo W, "Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation" 62 : 285-297, 2013

42 Pramod Darvin ; Salman M. Toor ; Varun Sasidharan Nair ; Eyad Elkord, "Immune checkpoint inhibitors: recent progress and potential biomarkers" 생화학분자생물학회 50 : 1-11, 2018

43 Hargadon KM, "Immune checkpoint blockade therapy for cancer : an overview of FDA-approved immune checkpoint inhibitors" 62 : 29-39, 2018

44 Van Hoecke L, "How mRNA therapeutics are entering the monoclonal antibody field" 17 : 54-, 2019

45 Jäger V, "High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells" 13 : 52-, 2013

46 Varkouhi AK, "Endosomal escape pathways for delivery of biologicals" 151 : 220-228, 2011

47 Semple SC, "Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids : formation of novel small multilamellar vesicle structures" 1510 : 152-166, 2001

48 Lu RM, "Development of therapeutic antibodies for the treatment of diseases" 27 : 1-, 2020

49 Tateshita N, "Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine" 310 : 36-46, 2019

50 de Macedo AL, "Development of CAR-T cell therapy for B-ALL using a point-of-care approach" 9 : 1752592-, 2020

51 Van der Jeught K, "Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety" 12 : 9815-9829, 2018

52 Lou G, "Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles : the impact of cationic lipid selection" 325 : 370-379, 2020

53 Zhou S, "Delivery of nucleic acid therapeutics for cancer immunotherapy" 6 : 100023-, 2020

54 Miao L, "Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation" 37 : 1174-1185, 2019

55 Zhang H, "Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling" 118 : e2005191118-, 2021

56 Huertas P, "Cotranscriptionally formed DNA : RNA hybrids mediate transcription elongation impairment and transcription-associated recombination" 12 : 711-721, 2003

57 Cui S, "Correlation of the cytotoxic effects of cationic lipids with their headgroups" 7 : 473-479, 2018

58 Mirzaei HR, "Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor(huCAR)-expressing primary human T cells" 234 : 9207-9215, 2019

59 Jahanafrooz Z, "Comparison of DNA and mRNA vaccines against cancer" 25 : 552-560, 2020

60 Ou W, "Combination of NIR therapy and regulatory T cell modulation using layer-by-layer hybrid nanoparticles for effective cancer photoimmunotherapy" 8 : 4574-4590, 2018

61 Ewert KK, "Cationic liposome–nucleic acid complexes for gene delivery and silencing : pathways and mechanisms for plasmid DNA and siRNA" 296 : 191-226, 2010

62 Malone RW, "Cationic liposome-mediated RNA transfection" 86 : 6077-6081, 1989

63 Lonez C, "Cationic lipids activate intracellular signaling pathways" 64 : 1749-1758, 2012

64 Heyes J, "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids" 107 : 276-287, 2005

65 Decker WK, "Cancer immunotherapy : historical perspective of a clinical revolution and emerging preclinical animal models" 8 : 829-, 2017

66 Oiseth SJ, "Cancer immunotherapy : a brief review of the history, possibilities, and challenges ahead" 3 : 250-261, 2017

67 Mohanty R, "CAR T cell therapy : a new era for cancer treatment(Review)" 42 : 2183-2195, 2019

68 Fenton OS, "Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery" 28 : 2939-2943, 2016

69 Suzuki Y, "Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates" 519 (519): 34-43, 2017

70 Liu C, "Barriers and strategies of cationic liposomes for cancer gene therapy" 18 : 751-764, 2020

71 Guevara ML, "Advances in lipid nanoparticles for mRNA-based cancer immunotherapy" 8 : 589959-, 2020

72 Lee K, "Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy" 8 : 1101-1105, 2020

73 Tossberg JT, "A simplified method to produce mRNAs and functional proteins from synthetic doublestranded DNA templates" 69 : 281-288, 2020

74 Esfahani K, "A review of cancer immunotherapy : from the past, to the present, to the future" 27 : S87-S97, 2020

75 Sabnis S, "A novel amino lipid series for mRNA delivery : improved endosomal escape and sustained pharmacology and safety in non-human primates" 26 (26): 1509-1519, 2018

76 Waldman AD, "A guide to cancer immunotherapy : from T cell basic science to clinical practice" 20 : 651-668, 2020